Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease

No Thumbnail Available
Files
There are no files associated with this item.
Date
2006
Authors
Dietz, Gunnar P. H.
Valbuena, Paoloa C.
Dietz, Birgit
Meuer, Katrin
Weishaupt, Jachen H.
Bähr, Mathias
Editors
Contact
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
URI (citable link)
ArXiv-ID
International patent number
Link to the license
EU project number
Project
Open Access publication
Collections
Restricted until
Title in another language
Research Projects
Organizational Units
Journal Issue
Publication type
Journal article
Publication status
Published
Published in
Brain Research ; 1082 (2006), 1. - pp. 61-66. - Elsevier. - ISSN 0006-8993. - eISSN 1872-6240
Abstract
Glial-cell-line-derived neurotrophic factor (GDNF) promotes mesencephalic dopaminergic neuronal survival in several in vitro and in vivo models. As the demise of dopaminergic neurons is the cause for Parkinson's disease (PD) symptoms, GDNF is a promising agent for its treatment. However, this neurotrophin is unable to cross the blood-brain barrier, which has complicated its clinical use. Therefore, ways to deliver GDNF into the central nervous system in an effective manner are needed. The HIV-1-Tat-derived cell-penetrating peptide (CPP) provides a means to deliver fusion proteins into the brain. We generated a fusion protein between the 11 amino acid CPP of Tat and the rat GDNF mature protein to deliver GDNF across the blood-brain barrier. We showed previously that Tat-GDNF enhances the neuroprotective effect of GDNF in in vivo models for nerve trauma and ischemia. Here, we tested its effect in a subchronic scheme of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) application into the mouse as a model for PD to evaluate the effect of Tat-GDNF fusion protein in dopaminergic neuron survival. We showed that the fusion protein did indeed reach the dopaminergic neurons. However, the in vivo application of Tat-GDNF did not provide neuroprotection of dopaminergic neurons, as revealed by immunohistochemistry and counting of the number of tyrosine-hydroxylase-immunoreactive neurons in the substantia nigra pars compacta. Possibly, GDNF does protect nigro-striatal projections of those neurons that survive MPTP treatment but does not increase the number of surviving dopaminergic neurons. A concomitant treatment of Tat-GDNF with an anti-apoptotic Tat-fusion protein might be beneficial.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Cell-penetrating peptide (CPP), Protein transduction domain (PTD), Blood–brain barrier, Neuroprotection, MPTP mouse model
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690DIETZ, Gunnar P. H., Paoloa C. VALBUENA, Birgit DIETZ, Katrin MEUER, Patrick MÜLLER, Jachen H. WEISHAUPT, Mathias BÄHR, 2006. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. In: Brain Research. Elsevier. 1082(1), pp. 61-66. ISSN 0006-8993. eISSN 1872-6240. Available under: doi: 10.1016/j.brainres.2006.01.083
BibTex
@article{Dietz2006-04-12Appli-55873,
  year={2006},
  doi={10.1016/j.brainres.2006.01.083},
  title={Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease},
  number={1},
  volume={1082},
  issn={0006-8993},
  journal={Brain Research},
  pages={61--66},
  author={Dietz, Gunnar P. H. and Valbuena, Paoloa C. and Dietz, Birgit and Meuer, Katrin and Müller, Patrick and Weishaupt, Jachen H. and Bähr, Mathias}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/55873">
    <dc:contributor>Bähr, Mathias</dc:contributor>
    <dc:creator>Dietz, Gunnar P. H.</dc:creator>
    <dc:creator>Müller, Patrick</dc:creator>
    <dcterms:title>Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease</dcterms:title>
    <dc:contributor>Dietz, Gunnar P. H.</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/55873"/>
    <dc:creator>Valbuena, Paoloa C.</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>2006-04-12</dcterms:issued>
    <dc:creator>Bähr, Mathias</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-12-14T09:37:07Z</dcterms:available>
    <dc:contributor>Valbuena, Paoloa C.</dc:contributor>
    <dc:contributor>Meuer, Katrin</dc:contributor>
    <dcterms:abstract xml:lang="eng">Glial-cell-line-derived neurotrophic factor (GDNF) promotes mesencephalic dopaminergic neuronal survival in several in vitro and in vivo models. As the demise of dopaminergic neurons is the cause for Parkinson's disease (PD) symptoms, GDNF is a promising agent for its treatment. However, this neurotrophin is unable to cross the blood-brain barrier, which has complicated its clinical use. Therefore, ways to deliver GDNF into the central nervous system in an effective manner are needed. The HIV-1-Tat-derived cell-penetrating peptide (CPP) provides a means to deliver fusion proteins into the brain. We generated a fusion protein between the 11 amino acid CPP of Tat and the rat GDNF mature protein to deliver GDNF across the blood-brain barrier. We showed previously that Tat-GDNF enhances the neuroprotective effect of GDNF in in vivo models for nerve trauma and ischemia. Here, we tested its effect in a subchronic scheme of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) application into the mouse as a model for PD to evaluate the effect of Tat-GDNF fusion protein in dopaminergic neuron survival. We showed that the fusion protein did indeed reach the dopaminergic neurons. However, the in vivo application of Tat-GDNF did not provide neuroprotection of dopaminergic neurons, as revealed by immunohistochemistry and counting of the number of tyrosine-hydroxylase-immunoreactive neurons in the substantia nigra pars compacta. Possibly, GDNF does protect nigro-striatal projections of those neurons that survive MPTP treatment but does not increase the number of surviving dopaminergic neurons. A concomitant treatment of Tat-GDNF with an anti-apoptotic Tat-fusion protein might be beneficial.</dcterms:abstract>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:contributor>Weishaupt, Jachen H.</dc:contributor>
    <dc:creator>Dietz, Birgit</dc:creator>
    <dc:creator>Weishaupt, Jachen H.</dc:creator>
    <dc:contributor>Dietz, Birgit</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-12-14T09:37:07Z</dc:date>
    <dc:contributor>Müller, Patrick</dc:contributor>
    <dc:rights>terms-of-use</dc:rights>
    <dc:creator>Meuer, Katrin</dc:creator>
    <dc:language>eng</dc:language>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
  </rdf:Description>
</rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Contact
URL of original publication
Test date of URL
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
No
Refereed
Yes